Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(5):365–370. doi: 10.1002/clc.4960230512

Cardiac sympathetic activity in the asymmetrically hypertrophied septum in patients with hypertension or hypertrophic cardiomyopathy

Masami Shimizu 1,✉, Hidekazu Ino 1, Kazuyasu Okeie 1, Yorito Emoto 1, Masato Yamaguchi 1, Toshihiko Yasuda 1, Noboru Fujino 1, Hiroyuki Fujii 1, Shinichiro Fujita 1, Hiroshi Mabuchi 1, Kenichi Nakajima 2, Junichi Taki 2
PMCID: PMC6654774  PMID: 10803446

Abstract

Background: In patients with essential hypertension (HT), proportional (symmetric) left ventricular hypertrophy (LVH) is common. In contrast, hypertrophic cardiomyopathy (HCM) is characterized by disproportional LVH and, in particular, asymmetric septal hypertrophy (ASH); however, some hypertensive patients also develop ASH. It has not been determined whether such cases represent a distinct type of hypertensive LVH or HCM combined with hypertension.

Hypothesis: The study was undertaken to evaluate sympathetic activity in the interventricular septum in patients with HT and ASH or in patients with HCM.

Methods: The patients were evaluated by I–123 metaiodobenzylguanidine (MIBG) and thallium‐201 (201Tl) single‐photon emission computed tomography (SPECT), respectively. They were divided into three groups: patients with essential HT and symmetric septal hypertrophy (Group A), patients with HT and ASH (Group B), and patients with HCM and ASH (Group C).

Results: Compared with the lateral wall, early uptake of MIBG in the septum was significantly higher in Group B than in Group A, but not significantly different between Groups A and C. Compared with the lateral wall, early uptake of 201Tl in the septum did not differ among the three groups. No significant difference in the MIBG clearance in the lateral wall was seen among the three groups. By contrast, MIBG clearances in the septum and apex were significantly greater in Group C than in Groups A and B. There was an inverse correlation between systolic thickening and MIBG clearance in the septum.

Conclusion: These findings suggest that sympathetic activity in the septum differs between patients with HT and ASH and patients with HCM.

Keywords: meta‐iodobenzylguanidine, asymmetric septal hypertrophy, hypertension, hypertrophic cardiomyopathy

Full Text

The Full Text of this article is available as a PDF (633.6 KB).

Reference

  • 1. Abbasi AS, MacAlpin RN, Eber LM, Pearce ML: Echocardiographic diagnosis of idiopathic hypertrophic cardiomyopathy without outflow obstruction. Circulation 1972; 46: 897–904 [DOI] [PubMed] [Google Scholar]
  • 2. Henry WL, Clark CE, Epstein SE: Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation 1973; 47: 225–233 [DOI] [PubMed] [Google Scholar]
  • 3. Toshima H, Koga Y, Yoshioka H, Akiyoshi T, Kimura N: Echocardiographic classification of hypertensive heart disease. A correlative study with clinical features. Jpn Heart J 1975; 16: 377–393 [DOI] [PubMed] [Google Scholar]
  • 4. Abi‐samra F, Fouad FM, Tarazi RC: Determinants of left ventricular hypertrophy and function in hypertensive patients. An echocardiographic study. Am J Med 1983; 75: 26–33 [DOI] [PubMed] [Google Scholar]
  • 5. Verdecchia P, Porcellati C, Zampi I, Schillaci G, Gatteschi C, Battistelli M, Bartoccini C, Borgioni C, Ciucci A: Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses. Am J Cardiol 1994; 73: 247–252 [DOI] [PubMed] [Google Scholar]
  • 6. Iida K, Sugishita Y, Matsuda M, Yamaguchi T, Ajisaka R, Matsumoto R, Fujita T, Yukisada K, Ito I: Difference in the response to isoproterenol between asymmetric septal hypertrophy and symmetric hypertrophy in patients with hypertrophic cardiomyopathy. Clin Cardiol 1986; 9: 7–12 [DOI] [PubMed] [Google Scholar]
  • 7. Raum WJ, Laks MM, Garner D, Swerdloff RS: b̃‐adrenergic receptor and cyclic AMP alterations in the canine ventricular septum during long‐term norepinephrine infusion: Implications for hypertrophic cardiomyopathy. Circulation 1983; 68: 693–699 [DOI] [PubMed] [Google Scholar]
  • 8. Bernardi D, Bernini L, Cini G, Ghione S, Bonechi I: Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. Am Heart J 1985; 109: 539–545 [DOI] [PubMed] [Google Scholar]
  • 9. Brush JE Jr, Eisenhofer G, Garty M, Stull R, Maron BJ, Cannon RO III, Panza JA, Epstein SE, Goldstein DS: Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 1989; 79: 836–844 [DOI] [PubMed] [Google Scholar]
  • 10. Schafers M, Dutka D, Rhodes CG, Lammertsma AA, Hermansen F, Schober O, Camici PG: Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998; 82: 57–62 [DOI] [PubMed] [Google Scholar]
  • 11. Simpson P, McGrath A: Norepinephrine‐stimulated hypertrophy of cultured rat myocardial cells is an alpha‐1 adrenergic response. J Clin Invest 1983; 72: 732–738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, Ugolini V, Akers MS, Hansen C, Buja LM, Parkey RW, Willerson JT: Abnormal I‐123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192–1199 [DOI] [PubMed] [Google Scholar]
  • 13. Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K: Quantitative analysis of 123I‐metaiodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 1990; 119: 1329–1337 [DOI] [PubMed] [Google Scholar]
  • 14. Brockenbrough EC, Braunwald E, Morrow AG: A hemodynamic technic for the detection of hypertrophic subaortic stenosis. Circulation 1961; 23: 189–194 [Google Scholar]
  • 15. Shimizu M, Sugihara N, Kita Y, Shimizu K, Horita Y, Nakajima K, Taki J, Takeda R: Long term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J 1992; 67: 155–160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Maron BJ, Edwards JE, Ferrans VJ, Clark CE, Lebowitz EA, Henry WL, Epstein SE: Congenital heart malformations associated with disproportionate ventricular septal thickening. Circulation 1975; 52: 926–932 [DOI] [PubMed] [Google Scholar]
  • 17. Abbasi AS, Slaughter JC, Allen MW: Asymmetric septal hypertrophy in patients on long‐term hemodialysis. Chest 1978; 74: 548–551 [DOI] [PubMed] [Google Scholar]
  • 18. Hess OM, Schneider J, Turina M, Carroll JD, Rothlin M, Krayenbuehl HP: Asymmetric septal hypertrophy in patients with aortic stenosis: An adaptive mechanism or a coexistence of hypertrophic cardiomyopathy? J Am Coll Cardiol 1983; 1: 783–789 [DOI] [PubMed] [Google Scholar]
  • 19. Karam R, Lever HM, Healy BP: Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension? A study of 78 patients. J Am Coll Cardiol 1989; 13: 580–584 [DOI] [PubMed] [Google Scholar]
  • 20. Kawai C, Yui Y, Hoshino T, Sasayama S, Matsumori A: Myocardial catecholamine in hypertrophic and dilated (congestive) cardiomyopathy: A biopsy study. J Am Coll Cardiol 1983; 2: 834–840 [DOI] [PubMed] [Google Scholar]
  • 21. Merlet P, Valette H, Dubois‐Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A: Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471–477 [PubMed] [Google Scholar]
  • 22. Lefroy DC, Silva R, Choudhury L, Uren NG, Crake T, Rhodes CG, Lammertsma AA, Boyd H, Patsalos PN, Nihoyannopoulos P, Oakley CM, Jones T, Camici PG: Diffuse reduction of myocardial beta‐adrenoceptors in hypertrophic cardiomyopathy: A study with positron emission tomography. J Am Coll Cardiol 1993; 22: 1653–1660 [DOI] [PubMed] [Google Scholar]
  • 23. Nakajima K, Taki J, Tonami N, Hisada K: Decreased 123 I‐MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994; 15: 317–323 [DOI] [PubMed] [Google Scholar]
  • 24. Tazelaar HD, Billingham ME: The surgical pathology of hypertrophic cardiomyopathy. Arch Pathol Lab Med 1987; 111: 257–260 [PubMed] [Google Scholar]
  • 25. Rabinovitch MA, Rose CP, Schwab AJ, Fitchett DH, Honos GH, Stewart JA, Chen LF, Castilla EP, Gomez AA, Abrahamowicz M: A method of dynamic analysis of iodine‐123‐metaiodobenzyl‐guanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993; 34: 589–600 [PubMed] [Google Scholar]
  • 26. Mitani I, Sumita S, Takahashi N, Ochiai H, Ishii M: 123 I‐MIBG myocardial imaging in hypertensive patients: Abnormality progresses with left ventricular hypertrophy. Ann Nucl Med 1996; 10: 315–321 [DOI] [PubMed] [Google Scholar]
  • 27. Morimoto S, Terada K, Keira N, Satoda M, Inoue K, Tatsukawa H, Katoh S, Ida K, Sugihara H, Takeda K, Nakagawa M: Investigation of the relationship between regression of hypertensive cardiac hypertrophy and improvement of cardiac sympathetic nervous dysfunction using iodine‐123 metaiodobenzylguanidine myocardial imaging. Eur J Nucl Med 1996; 23: 756–761 [DOI] [PubMed] [Google Scholar]
  • 28. Geisterfer‐Lowrance AAT, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG: A molecular basis for familial hypertrophic cardiomyopathy: A b̃ cardiac myosin heavy chain gene missense mutation. Cell 1990; 62: 999–1006 [DOI] [PubMed] [Google Scholar]
  • 29. Schwartz K, Carrier L, Guicheney P, Komajda M: Molecular basis of familial cardiomyopathies. Circulation 1995; 91: 532–540 [DOI] [PubMed] [Google Scholar]
  • 30. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE: α‐tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell 1994; 77: 701–712 [DOI] [PubMed] [Google Scholar]
  • 31. Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, Hiroi S, Sasaoka T, Ohbuchi N, Nakamura T, Koyanagi T, Hwang TH, Choo JA, Chung KS, Hasegawa A, Nagai R, Okazaki O, Nakamura H, Matsuzaki M, Sakamoto T, Toshima H, Koga Y, Imaizumi T, Sasazuki T: Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nature Genet 1997; 16: 379–382 [DOI] [PubMed] [Google Scholar]
  • 32. Carrier L, Bonne G, Bahrend E, Yu B, Richard P, Niel F, Hainque B, Cruaud C, Gary F, Labeit S, Bouhour JB, Dubourg O, Desnos M, Hagege AA, Trent RJ, Komajda M, Fiszman M, Schwarz K: Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res 1997; 80: 427–434 [PubMed] [Google Scholar]
  • 33. Ungerer M, Hartmann F, Karoglan M, Chlistalla A, Ziegler S, Richardt G, Overbeck M, Meisner H, Schomig A, Schwaiger M: Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 1998; 97: 174–180 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES